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Cisplatin is a potent cytotoxic agent used for the treatment of
ovarian and testicular cancer and other malignancies.1 The cyto-
toxicity of cisplatin is thought to be related to its ability to modify
cellular DNA.2 In plasma, where the chloride concentration is∼105
mM, cisplatin is believed to partially solvate to its aquated forms.3
Since aquated complexes can react with components present in
blood and the cytosol, they may be important for the antitumor
effects, resistance, and toxicity associated with cisplatin.4
Earlier, we used HSQC NMR and low concentrations of15N-
labeled cisplatin,cis-Pt(15NH3)2Cl2 (1, Figure 1), to identify the
platinum species in culture media (RPMI+ 10% fetal bovine
serum) in the presence and absence of Jurkat cells.5 We interpreted
the NMR measurements as showing that1 hydrolyzes to the
monoaquo complex,2, which is in equilibrium with the monohy-
droxo species,3, as is known to occur in aqueous solution.3 We
found that, with more than 5× 106 cells present,2 had disappeared
by 0.5 h, the earliest time for which NMR measurements could be
made. In the absence of cells, however, the NMR signal ascribed
to 2 persisted to>20 h, which was unexpected because aquated
species should react more quickly than1 with components in the
medium. To identify species having NMR signatures similar to that
of 2 but with reduced reactivity, we studied the reaction of1 in
carbonate buffer6 and in culture media with and without carbonate
ion. In this report, we show that, in the presence of carbonate,1
reacts to form the carbonato complex4, which is the long-lived
species observed in the cell culture studies. At long times in
carbonate buffer,4 reacts to form5. Since carbonate is present in
blood at high concentrations and it may react with1, these
observations have potentially important implications for the uptake,
antitumor properties, and toxicity of cisplatin.
As we have earlier shown,5 [1] decreases with time in culture
media approximately at the rate expected for the hydrolysis of1 t
2.3 However, the resonance assigned to2 (3) was not observed in
NMR studies in culture medium deficient in carbonate ion, whereas
it was observed in studies in carbonate buffer alone. Thus, the
species present in the earlier reported cell culture studies is not2
but, rather, the carbonato complex,4.
The HSQC NMR spectrum of 65µM cisplatin, in carbonate
buffer, is shown in Figure 2. The peak for Ntrans to O of
compound4 is at 1H/15N, δ ) 3.61/-80.5, while the peak for N
trans to Cl of the compound is under the peak for1.5 The peak for
N transto O of4 disappears with time, and a new compound forms,
having a peak at1H/15N, δ ) 3.70/-81.8. This has been assigned
to the biscarbonato complex5. The HSQC NMR data for4 and5
are consistent with assignments made for similar compounds.3b The
concentrations of the three compounds,1, 4, and5, are shown as
functions of time in Figure 3 and are discussed below.
A 1 mM solution of 14N 1 and 5 mM NaH13CO3 was studied
using 1D13C NMR.8 The spectrum showed resonances at13C, δ )
160.8, 125.3, and 167.0 ppm, corresponding to HCO3-, CO2(aq),
and5, respectively. The chemical shifts of the carbonates in5 are
at ∼1 ppm higher field than that of the corresponding bidentate
carbonate incis-bistriethylphosphine carbonato platinum(II) and at
∼4 ppm higher field than that of a bridging carbonate in a dinuclear
complex of Zn2+.9
By analysis of UV absorption data, it was determined that
compound5 has ad-d absorption band at 268 nm, which is shifted
to higher energy relative to the maind-d band for1. Since the
crystal field strength of CO3-2 is greater than that of Cl-, this shift
to higher energy for5 is expected.10
Compounds1 and5 each have a single HSQC NMR peak, but
4 has two equal peaks, one overlapping the peak for1. The true
intensity of1 is obtained by subtracting the apparent intensity of4
from the apparent intensity of1, and the true intensity of4 is double
the apparent intensity of4. These true intensities are proportional
to species concentrations, so, given the total Pt concentration, one
can convert intensities to concentrations, giving the points of Figure
3. The curves in Figure 3 are best-fit curves for the reaction scheme
shown in Figure 1. The rate constants for conversion of1 t 2 and
Figure 1. Reaction of cisplatin with carbonate.
Figure 2. 1H-15N HSQC NMR spectrum of 65µM 1 in 5 mM HCO3-,
[Cl-] ) 3.3 mM, 37° C, t ) 11.6 h.
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the reverse are known from previous work.3a,b By analogy with
other metal complexes,6,11 compound4 can be formed by reaction
of CO2 with 3 and/or reaction of CO3-2 with 2. The rate constants
for conversion of4 to 5 (by reaction with carbonate) and the reverse
are parameters in the model. The fit is excellent, confirming that,
in 5 mM carbonate buffer,1 disappears to form4, which then yields
5. In 0.5 mM carbonate, the conversion of1 to 4 occurs at the
same rate as that in 5 mM carbonate, but5 is formed much less
rapidly. This shows that the rate of conversion of4 to 5 is carbonate-
dependent.
Although5 is observed in carbonate buffer, it is not observed in
culture media.5 This may be due to the high chloride content of
the medium which suppresses the formation of5 and/or rapid
reaction of the compound with the many possible nucleophiles
present in the medium. Low concentrations of the compound would
be more difficult to detect with HSQC NMR.
It is known that hydrating patients with hypertonic saline
solutions reduces the renal toxicity of cisplatin.4a,bSince increased
chloride concentration in blood would shift the equilibria in Figure
1 to the left, reducing the concentration of carbonato species, it
may be that the latter are, in part, responsible for some of the toxic
effects observed with cisplatin. However, work with relevant renal
cells will be necessary in order to show if this is the case.
The fate of4, which quickly disappears from the HSQC NMR
spectrum when Jurkat cells are present, is unknown.5 However, it
is possible that this species is selectively taken up by the cell. It is
important to note that the heavy metal ion Cd2+ forms carbonate
complexes which are taken up by cells and that anion exchangers
found in the plasma membrane may be involved in its transport.12
Work in progress will determine if a similar uptake mechanism is
involved with carbonato complexes of cisplatin.
In this work, we use low concentrations of113 to show that the
earlier detected cisplatin metabolite that forms in culture media,
and is taken up/modified by cells,5 is the carbonato complex,4. In
carbonate buffer,4 slowly reacts to form the biscarbonato complex,
5. Since the carbonate concentrations in culture media, plasma,
and the cytosol are similar, platinum carbonato complexes may be
present in therapy, and they could be the species reacting with
components in the cell. Despite the large body of work on cisplatin
and its analogues, little attention has been paid to the potential role
of carbonate ion in these reactions.14 Hopefully, this report will
stimulate new inquiry on the role of carbonate in the mechanism
of action of platinum anticancer drugs.
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Figure 3. Concentrations of1 (blue, squares),4 (red, triangles), and5
(brown, circles) from NMR measurements, with fits to the model of Figure
1 (smooth curves).
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